Compare D R Horton Inc (DHI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Recursion Pharmaceuticals Inc — how do they compare? D R Horton Inc trades at $134.81 (market cap $37.99B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: D R Horton Inc is far larger — about 17.8× Recursion Pharmaceuticals Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DHI | RXRX | |
|---|---|---|
Market Cap | $37.99B | $2.14B |
Volume | 2,974,460 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $6.79 |
52-Week Low | $132.53 | $2.84 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | $43.09B | $1.66B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $134.88, up 1.2% on the day, with a bearish technical signal and neutral oscillators. The stock has beaten earnings estimates in recent quarters, with a P/E of 12.95 and net income margin of 9.15%. Recent news highlights pressure from rising mortgage rates, with the 30-year fixed rate potentially spiking to 9% according to Selma Hepp on CNBC (2026-09-28), impacting homebuilder sentiment.
The outlook is mixed: strong fundamentals and analyst consensus price target of $156.57 offer upside, but macroeconomic risks from interest rates and housing market weakness pose headwinds. Earnings growth remains a key catalyst, yet affordability concerns could dampen near-term performance.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
